Upload
jocelyn-reed
View
218
Download
1
Tags:
Embed Size (px)
Citation preview
Structure of Dossier of Medicinal Product- Q part
Gabriel K. Kaddu
Head, Drug Assessment and Registration
National Drug Authority
Training workshop: Training workshop on regulatory requirements for registration of Artemisinin based combined medicines and assessment of data submitted to regulatory authorities, February 23-27, 2009, Kampala, Uganda.
Artemisinin based combined medicinesFebruary 23-27, 2009, Kampala, Uganda 2 |
Structure of Dossier of Medicinal product Q part
Structure of Dossier of Medicinal product Q part
Outline of presentation
Objective of the presentation
The Common Technical Document (CTD) for the Registration of Pharmaceuticals for Human Use: Quality – M4Q MODULE 3: QUALITY
Guideline on Submission of documentation for Prequalification of Multi-source (Generic) Finished Pharmaceutical Products (FPPs) Used in the Treatment of HIV/AIDs, Malaria and Tuberculosis
Artemisinin based combined medicinesFebruary 23-27, 2009, Kampala, Uganda 3 |
Overview of Dossier Requirements and Guidelines
Overview of Dossier Requirements and Guidelines
Objective of the presentation:– To provide an overview of the dossier requirements and
Guidelines used or referenced under the WHO Prequalification Program
– To demonstrate how the requirements and guidelines can be applied or used as reference.
Artemisinin based combined medicinesFebruary 23-27, 2009, Kampala, Uganda 4 |
Overview of Dossier Requirements and Guidelines (1)
Overview of Dossier Requirements and Guidelines (1)
Common Technical Document
(CTD)
An initiative under the ICH: Europe, Japan and USA.
http://www.ich.org
Artemisinin based combined medicinesFebruary 23-27, 2009, Kampala, Uganda 5 |
Structure of dossier of medicinal products, information on the CTD format (1)
Structure of dossier of medicinal products, information on the CTD format (1)
A common format for the technical documentation:– significantly reduces the time and resources needed to compile
applications for registration of human pharmaceuticals– eases the preparation of electronic submissions– Facilitates regulatory reviews and communication with the
applicant by a standard document of common elements– Simplifies exchange of regulatory information between
Regulatory Authorities
This guideline is not intended to indicate what studies are required. It merely indicates an appropriate format for the data that have been acquired.
Artemisinin based combined medicinesFebruary 23-27, 2009, Kampala, Uganda 6 |
CTD format (2)CTD format (2)
GENERAL PRINCIPLES – Text and tables should be prepared using margins that allow the document
to be printed on A4 paper.– The left-hand margin should be sufficiently large that information is not
obscured by the method of binding.– Font sizes for text and tables should be easily legible, even after
photocopying. Times New Roman, 12-point font, is recommended for narrative text.
– Every page should be numbered.– Acronyms and abbreviations should be defined the first time they are used
in each module.– References should be cited in accordance with the current edition of the
Uniform Requirements for Manuscripts Submitted to Biomedical Journals, International Committee of Medical Journal Editors (ICMJE)1.
Artemisinin based combined medicinesFebruary 23-27, 2009, Kampala, Uganda 7 |
CTD format (3)CTD format (3)
The CTD is organized into five modules:– Module 1 is region specific.– Modules 2, 3, 4, and 5 are intended to be common for all regions.
Module 1. Administrative Information and Prescribing Information
– Should contain documents specific to each region; e.g. application forms or the proposed label for use in the region. The content and format of this module can be specified by the relevant regulatory authorities.
Module 1: Administrative Information and Prescribing Information – 1.1 Table of Contents of the Submission Including Module 1 – 1.2 Documents Specific to Each Region (for example, application forms,
prescribing information)
Artemisinin based combined medicinesFebruary 23-27, 2009, Kampala, Uganda 8 |
CTD format (4)CTD format (4)
Module 2. Common Technical Document Summaries – Should begin with a general introduction to the pharmaceutical, including its pharmacological class, mode of
action, and proposed clinical use. In general, the Introduction should not exceed one page.– Should contain 7 sections in the following order :
• 2.1 Common Technical Document Table of Contents (Modules 2-5) • 2.2 CTD Introduction • 2.3 Quality Overall Summary • 2.4 Non-clinical Overview • 2.5 Clinical Overview • 2.6 Non-clinical Written and Tabulated Summaries
– Pharmacology – Pharmacokinetics – Toxicology
• 2.7 Clinical Summary – Biopharmaceutical Studies and Associated Analytical Methods – Clinical Pharmacology Studies – Clinical Efficacy – Clinical Safety – Literature References – Synopses of Individual Studies
Artemisinin based combined medicinesFebruary 23-27, 2009, Kampala, Uganda 9 |
CTD format (5)CTD format (5)
Module 3. Quality – Information on Quality should be presented in the structured
format described in Guideline M4Q.
Module 3: Quality – 3.1 Table of Contents of Module 3 – 3.2 Body of Data
– 3.3 Literature References
Artemisinin based combined medicinesFebruary 23-27, 2009, Kampala, Uganda 10 |
CTD format: Numbering System: Module 3CTD format: Numbering System: Module 3Module 3
3.1 MODULE 3 TABLE OF CONTENTS
3.2 BODY OF DATA
3.2.S DRUG SUBSTANCE
3.2.S.1 General Information
3.2.S.2 Manufacture
3.2.S.3 Characterisation
3.2.S.4 Control of Drug Substance
3.2.S.5 Reference Standards or Materials
3.2.S.6 Container Closure System
3.2.S.7 Stability
3.2.P DRUG PRODUCT
3.2.P.1 Description and Composition of the Drug Product
3.2.P.2 Pharmaceutical Development
3.2.P.3 Manufacture
3.2.P.4 Control of Excipients 3.2.P.5 Control of Drug Product 3.2.P.6 Reference Standards or Materials 3.2.P.7 Container Closure System 3.2.P.8 Stability
Module 3 (Cont.)
3.2.A APPENDICES
3.2.A.1 Facilities and Equipment
3.2.A.2 Adventitious Agents Safety Evaluation
3.2.A.3 Novel Excipients
3.2.R REGIONAL INFORMATION
3.3 LITERATURE REFERENCES
Artemisinin based combined medicinesFebruary 23-27, 2009, Kampala, Uganda 11 |
Overview of Dossier Requirements and Guidelines (2)
Overview of Dossier Requirements and Guidelines (2)
Guideline on Submission of documentation for Prequalification of Multi-source (Generic) Finished Pharmaceutical Products (FPPs) Used in the Treatment of HIV/AIDs, Malaria and Tuberculosis
http://mednet3.who.int/prequal
Artemisinin based combined medicinesFebruary 23-27, 2009, Kampala, Uganda 12 |
Generic Guide: Documentation on Quality Part to be submitted to the WHO PQ teamGeneric Guide: Documentation on Quality Part to be submitted to the WHO PQ team
Covering letter
Product dossier on Quality part
PQIF (annex 8 to the main generic guide): properly filled out in WinWord format, www.who.int/prequal/
Artemisinin based combined medicinesFebruary 23-27, 2009, Kampala, Uganda 13 |
Generic Guide: Quality dossier / Section 1Generic Guide: Quality dossier / Section 1
Information on the Finished Pharmaceutical Product (FPP)
1.1. Details of the Product- Name, dosage form and strength of the product- Approved generic name (INN)- Visual description of the FPP- Visual description of the packaging
1.2. Samples (visual examination and comparison with the SPC and PIL
1.3. Regulatory situation in Member States / list countries- Countries where a MA has been issued- Countries where a MA has been withdrawn- Countries where a Marketing Application has been rejected, deferred
Artemisinin based combined medicinesFebruary 23-27, 2009, Kampala, Uganda 14 |
Generic Guide:Generic Guide:
Quality dossier / Section 2
Active Pharmaceutical Ingredient (API)
Artemisinin based combined medicinesFebruary 23-27, 2009, Kampala, Uganda 15 |
Generic Guide: Quality/Section 2: APIGeneric Guide: Quality/Section 2: API
Scientific data on the API can be submitted in the following order of preference
A valid Certificate of Suitability (CoS) or CEP, latest version, with all its annexes issued by EDQM
An APIMF (Active Pharmaceutical Ingredient Master File) submitted by the API manufacturer, containing the whole information requested in section 2
Complete submission of data requested in Section 2
Artemisinin based combined medicinesFebruary 23-27, 2009, Kampala, Uganda 16 |
Generic Guide: Quality/Section 2: APIComplete submission option
Generic Guide: Quality/Section 2: APIComplete submission option
2.1. Nomenclature (INN, chemical name, CAS No.)
2.2. Properties of the API**
2.3. Site(s) of manufacture
2.4. Route(s) of synthesis**
2.5. Specifications**
2.6. Container- closure system
2.7. Stability testing
** The requirements may differ depending on if the API is pharmacopoeial or non-pharmacopoeial
Artemisinin based combined medicinesFebruary 23-27, 2009, Kampala, Uganda 17 |
Generic Guide: Quality/Section 2: API, Certification of Suitability (CoS) / CEP Option
Generic Guide: Quality/Section 2: API, Certification of Suitability (CoS) / CEP Option Issued by EDQM for substances described in the Ph. Eur. www.edqm.eu
2 types of CEPs: quality CEP and TSE CEP
Information which can be found on a quality CEP CEP reference, CEP holder, site of manufacture of the substance, monograph according to which the dossier is evaluated, additional impurities and residual solvents not mentioned in the monograph, additional methods to those of the monograph are appended, re-test period with packaging system and storage condition (if applicable), date of validity of the CEP
A quality CEP certifies that the quality of the substance can be checked according to the Ph. Eur. by applying the analytical methods described in the Ph. Eur. monograph supplemented by those
appended to the CEP.
Artemisinin based combined medicinesFebruary 23-27, 2009, Kampala, Uganda 18 |
Generic Guide: Quality/Section 2: API, APIMF Option
Generic Guide: Quality/Section 2: API, APIMF Option
Procedure implemented since January 2007, www.who.int/prequal
To protect the "know-how" of the manufacturer of the API – While giving the whole information on manufacture of the API to the
WHO PQ team of assessors– While giving a part of the information to the applicant to
Prequalification/ manufacturer of the finished product
An APIMF is composed of: Applicant's /Open part + Restricted / Closed part
Manufacturer of the API should make available to the applicant to Prequalification the Applicant's part + Letter of access
Artemisinin based combined medicinesFebruary 23-27, 2009, Kampala, Uganda 19 |
Generic Guide: Quality/Section 2: API. APIMF Option
Generic Guide: Quality/Section 2: API. APIMF Option
Manufacturer of the API should submit on the other hand the Applicant's part + Restricted + Letter of access to WHO team An APIMF is to be submitted only in support of a FPP dossier
An APIMF is not an independent dossier of API
Scope open to pharmacopoeial and non-pharmacopoeial APIs
Scope of APIMF only open to APIs
See annex 1 of the APIMF guide for the content of an APIMF
Content of APIMF corresponds to data required in section 2 of the prequalification quality dossier without difference between pharmacopoeial and non-pharmacopoeial APIs
Artemisinin based combined medicinesFebruary 23-27, 2009, Kampala, Uganda 20 |
Generic Guide:Generic Guide:
Quality dossier / Section 3
Finished Pharmaceutical Product
(FPP)
Artemisinin based combined medicinesFebruary 23-27, 2009, Kampala, Uganda 21 |
Generic Guide: Quality/Section 3: FPPGeneric Guide: Quality/Section 3: FPP
3.1. Manufacturing and marketing authorization
3.2. Pharmaceutical development
3.3. Formulation
3.4. Sites of manufacture
3.5. Manufacturing process
3.6. Manufacturing process controls of Critical steps and intermediates
3.7. Process validation and Evaluation
3.8. Specifications for excipients
3.9. Control of the FPP
3.10. Container/closure system (s) and other packaging
3.11. Stability testing
Artemisinin based combined medicinesFebruary 23-27, 2009, Kampala, Uganda 22 |
Generic Guide: Quality/Section 3: FPPGeneric Guide: Quality/Section 3: FPP
3.12. Container labelling
3.13. Product information for health professionals
3.14. Patient information and package leaflet
3.15. Justification for any differences to the product in the country or countries issuing the submitted WHO-type certificate(s)